AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23561869 — intervention group
Group type: COMPARATOR
Intervention: Conventional group received mobilizations of the shoulder, along with electrotherapy and postural advice.
Number of subjects: 22
Study 21690318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking independent of nicotine
Number of subjects: 20
Study 21690318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking with nicotine yield (0.05, 0.6, or 0.9 mg)
Number of subjects: 20
Study 21690318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette self‐administration
Number of subjects: 20
Study 19841128 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ppm iNO
Number of subjects: 793
Study 19841128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study 16376428 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based screening using UPDRS3
Number of subjects: 2081
Study 16376428 — intervention group
Group type: COMPARATOR
Intervention: In-person examination using UPDRS3
Number of subjects: 2081
Study 16376428 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal diagnostic criteria for parkinsonism
Number of subjects: 2081
Study 16376428 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative diagnostic criteria for parkinsonism
Number of subjects: 2081
Study 15016032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% oxybenzone dentifrice
Number of subjects: 66
Study 15016032 — intervention group
Group type: COMPARATOR
Intervention: placebo dentifrice
Number of subjects: 66
Study 12951643 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a clinical trial (qualification phase of a Good Clinical Practice trial)
Number of subjects: 0
Study 10863219 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 169
Study 9190093 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy information intervention (written information package with discussion, list of questions for physician, audiotape of medical consultation)
Number of subjects: 60
Study 9190093 — intervention group
Group type: COMPARATOR
Intervention: Written information package alone (control group)
Number of subjects: 60
Study 1414966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in monounsaturated fatty acids, enriched with avocado (AE)
Number of subjects: 15
Study 1414966 — intervention group
Group type: COMPARATOR
Intervention: High-complex-carbohydrate diet (AHA-III)
Number of subjects: 15
Study 2882046 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of pilocarpine 2% and metipranolol 0.1%
Number of subjects: 0
Study 2882046 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 2% alone
Number of subjects: 0
Study 2882046 — intervention group
Group type: COMPARATOR
Intervention: Metipranolol 0.1% alone
Number of subjects: 0
Study 30613061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergenerational Exchange Program (IGEP) for older adults
Number of subjects: 42
Study 30613061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergenerational Exchange Program (IGEP) for preschool children
Number of subjects: 42
Study 30613061 — intervention group
Group type: COMPARATOR
Intervention: Control group (older adults)
Number of subjects: 42
Study 26862857 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine or UFT plus radiotherapy (RT)
Number of subjects: 17
Study 26862857 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine or UFT plus cetuximab plus RT
Number of subjects: 17
Study 26862857 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline plasma miR‐21
Number of subjects: 17
Study 24909509 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/oxaliplatin (GEMOX) plus erlotinib
Number of subjects: 268
Study 24909509 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/oxaliplatin (GEMOX) alone
Number of subjects: 268
Study 24909509 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic tumor volume (MTV) as a prognostic factor
Number of subjects: 268
Study 24909509 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum standardized uptake value (SUVmax)
Number of subjects: 268
Study 22103795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 177
Study 22103795 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 177
Study 20109331 — intervention group
Group type: EXPERIMENTAL
Intervention: CD gel
Number of subjects: 40
Study 20109331 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study 18096307 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic diagnosis (PDD) with hexaminolevulinate (Hexvix) solution
Number of subjects: 0
Study 18096307 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic diagnosis (PDD)
Number of subjects: 0
Study 15869144 — intervention group
Group type: COMPARATOR
Intervention: Conventional indicators of hypoperfusion (Group 1)
Number of subjects: 151
Study 15869144 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric tonometry-derived estimates of splanchnic hypoperfusion (Group 2)
Number of subjects: 151
Study 15869144 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies aimed at optimizing splanchnic perfusion (Group 3)
Number of subjects: 151
Study 12873920 — intervention group
Group type: EXPERIMENTAL
Intervention: IV test dose (0.1 mL/kg) consisting of 1% lidocaine with 1:200,000 epinephrine (epinephrine 0.5 microg/kg)
Number of subjects: 32
Study 12873920 — intervention group
Group type: COMPARATOR
Intervention: IV saline 0.1 mL/kg
Number of subjects: 32
Study 10723498 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily didanosine plus twice daily stavudine (group A)
Number of subjects: 84
Study 10723498 — intervention group
Group type: COMPARATOR
Intervention: Twice daily didanosine plus twice daily stavudine (group B)
Number of subjects: 84
Study 10723498 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 84
Study 7857095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (75 mg/body cisplatin, 150 mg/body etoposide, 10 mg/body mitomycin C, and oral 5-FU)
Number of subjects: 8
Study 7857095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 8
Study 7857095 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 8
Study 1958432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with good medication compliance (≥90% capsule consumption)
Number of subjects: 0
Study 1958432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with good medication compliance (≥90% positive gemfibrozil analyses)
Number of subjects: 0
Study 1958432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with good medication compliance (good compliance according to both digoxin marker measurements)
Number of subjects: 0
Study 1958432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with poor medication compliance (<50% capsule consumption)
Number of subjects: 0
Study 1958432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with poor medication compliance (<50% positive gemfibrozil analyses)
Number of subjects: 0
Study 1958432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment with poor medication compliance (poor results in both digoxin marker measurements)
Number of subjects: 0
Study 6890361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 300 mg
Number of subjects: 19
Study 6890361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 100 mg
Number of subjects: 19
Study 6890361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 500 mg
Number of subjects: 19
Study 6890361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 300 mg and 500 mg
Number of subjects: 19
Study 6890361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg
Number of subjects: 19
Study 6890361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 100-300 mg
Number of subjects: 19
Study 6890361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (any dose)
Number of subjects: 19
Study 30921503 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ/SAM (10 mg OLZ/10 mg SAM) in fed conditions
Number of subjects: 36
Study 30921503 — intervention group
Group type: COMPARATOR
Intervention: OLZ/SAM (10 mg OLZ/10 mg SAM) in fasted conditions
Number of subjects: 36
Study 26936430 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush allodynia
Number of subjects: 20
Study 26936430 — intervention group
Group type: COMPARATOR
Intervention: Semmes‐Weinstein monofilament
Number of subjects: 20
Study 26936430 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (Zostrix 0.075%)
Number of subjects: 20
Study 25368372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline, 1mg/d (n = 31)
Number of subjects: 60
Study 25368372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 60
Study 23851908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) treatment
Number of subjects: 61
Study 23851908 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV concentration at week 8
Number of subjects: 61
Study 23851908 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off value of week 8 RBV concentration
Number of subjects: 61
Study 23851908 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off values at weeks 1, 2, or 4
Number of subjects: 61
Study 21736853 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry beverage
Number of subjects: 24
Study 21736853 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 24
Study 19885051 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain control protocol
Number of subjects: 60
Study 19885051 — intervention group
Group type: COMPARATOR
Intervention: Conventional pain control protocol
Number of subjects: 60
Study 19885051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16443502 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group (100 women with abnormal OGTT)
Number of subjects: 200
Study 16443502 — intervention group
Group type: COMPARATOR
Intervention: Gly482Ser and Thr394Thr polymorphisms of the PGC‐1 gene
Number of subjects: 200
Study 16443502 — intervention group
Group type: COMPARATOR
Intervention: Different haplotype combinations of the two loci
Number of subjects: 200
Study 15001247 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (with rectangular fields) to a dose of 66 Gy
Number of subjects: 199
Study 15001247 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy to a dose of 66 Gy
Number of subjects: 199
Study 15001247 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated rectum volume at 60 Gy
Number of subjects: 199
Study 15001247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose levels between 25 Gy and 60 Gy
Number of subjects: 199
Study 15001247 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative DVHs of the rectal wall excluding the anal region at 60 Gy
Number of subjects: 199
Study 11669434 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse technique (Group B)
Number of subjects: 67
Study 11669434 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (Group A)
Number of subjects: 67
Study 9608433 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 9608433 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP 3174
Number of subjects: 0
Study 9608433 — intervention group
Group type: EXPERIMENTAL
Intervention: SL 91.0102‐90 DL
Number of subjects: 0
Study 9608433 — intervention group
Group type: EXPERIMENTAL
Intervention: UP 269‐6
Number of subjects: 0
Study 9608433 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 0
Study 8017308 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 200
Study 8017308 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 200
Study 8017308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 200
Study 2689471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 184
Study 2689471 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 184
Study 2689471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 773907 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolin 2% (formaldehyde releasing antimicrobial)
Number of subjects: 16
Study 773907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vantocil 0.1% (polybiguanide)
Number of subjects: 16
Study 773907 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride 0.025%
Number of subjects: 16
Study 773907 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 16
Study 7225912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.75%
Number of subjects: 7
Study 7225912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 7
Study 30635038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary exercise group (PG)
Number of subjects: 0
Study 30635038 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise group (RG)
Number of subjects: 0
Study 30635038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pulmonary exercise and resistance exercise group (PRG)
Number of subjects: 0
Study 30635038 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, CG)
Number of subjects: 0
Study 29131887 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 13557
Study 29131887 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 13557
Study 26848151 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 300mg BID
Number of subjects: 61
Study 26848151 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 200mg BID + Mitomycin C (10mg/m2 every 28 days)
Number of subjects: 61
Study 26848151 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib alone or with MMC
Number of subjects: 61
Study 25239483 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated SA 14-14-2 JE vaccine manufactured in a new GMP facility
Number of subjects: 818
Study 25239483 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated SA 14-14-2 JE vaccine manufactured in the original facility
Number of subjects: 818
Study 21626049 — intervention group
Group type: EXPERIMENTAL
Intervention: PDXG regimen (cisplatin, docetaxel, capecitabine, gemcitabine)
Number of subjects: 105
Study 21626049 — intervention group
Group type: COMPARATOR
Intervention: PEXG regimen (cisplatin, epirubicin, capecitabine, gemcitabine)
Number of subjects: 105
Study 19132807 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention based on healthcare management agreements including periodic educational meetings and economic incentives.
Number of subjects: 0
Study 17984738 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350 laxative (MiraLax) 17 g per day for 28 days
Number of subjects: 100
Study 17984738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17984738 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350 laxative
Number of subjects: 100
Study 12950711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (mean dose = 888 +/- 418 mg at bedtime)
Number of subjects: 50
Study 12950711 — intervention group
Group type: COMPARATOR
Intervention: Trazodone (mean dose = 105 +/- 57 mg at bedtime)
Number of subjects: 50
Study 10786962 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibody to tumor necrosis factor
Number of subjects: 60
Study 10786962 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin 1 receptor antagonist
Number of subjects: 60
Study 9561598 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-HB vaccine administered at 2, 4, and 6 months
Number of subjects: 160
Study 9561598 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-HB vaccine
Number of subjects: 160
Study 9561598 — intervention group
Group type: EXPERIMENTAL
Intervention: HB vaccination at birth followed by DTP-HB vaccine at 2, 4, 6, and 18 months
Number of subjects: 160
Study 1606541 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 102
Study 1606541 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 102
Study 1606541 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and Radiation therapy
Number of subjects: 102
Study 4036270 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml subcutaneously (SC)
Number of subjects: 60
Study 4036270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml intradermally (ID)
Number of subjects: 60
Study 4036270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml subcutaneously (SC)
Number of subjects: 60
Study 4036270 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml SC
Number of subjects: 60
Study 30770726 — intervention group
Group type: EXPERIMENTAL
Intervention: TaGT genes
Number of subjects: 2387
Study 30770726 — intervention group
Group type: EXPERIMENTAL
Intervention: BdGT genes
Number of subjects: 2387
Study 28111208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative intramuscular testosterone enanthate (2 mg/kg) administered in Group 2 (subdivided into Group 2A and Group 2B based on timing of surgery)
Number of subjects: 94
Study 28111208 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 94
Study 25872501 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the management algorithm for tuberculosis diagnosis and treatment in intervention clinics.
Number of subjects: 24
Study 25872501 — intervention group
Group type: COMPARATOR
Intervention: Standard of care in control clinics.
Number of subjects: 24
Study 23665364 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair with the MitraClip device
Number of subjects: 279
Study 23665364 — intervention group
Group type: COMPARATOR
Intervention: Conventional mitral valve surgery
Number of subjects: 279
Study 21878162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 57
Study 21878162 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 57
Study 21878162 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study 20031704 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-directed therapy
Number of subjects: 800
Study 20031704 — intervention group
Group type: COMPARATOR
Intervention: Angiography-directed therapy
Number of subjects: 800
Study 17192504 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR1766
Number of subjects: 18
Study 17192504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol (50 mg daily)
Number of subjects: 24182
Study 15205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (20 mg daily)
Number of subjects: 24182
Study 15205487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24182
Study 11252122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapies (aspirin and beta-adrenergic blocking agents)
Number of subjects: 183113
Study 11252122 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography and mechanical revascularization procedures
Number of subjects: 183113
Study 11252122 — intervention group
Group type: COMPARATOR
Intervention: Major severity clinical events
Number of subjects: 183113
Study 11252122 — intervention group
Group type: COMPARATOR
Intervention: Intermediate severity clinical events
Number of subjects: 183113
Study 11252122 — intervention group
Group type: COMPARATOR
Intervention: Minor severity clinical events
Number of subjects: 183113
Study 9161888 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment (4-week double-blind assessment)
Number of subjects: 39
Study 9161888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive testing on methylphenidate
Number of subjects: 39
Study 8120686 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice and feedback on silicone breast models and women volunteers
Number of subjects: 156
Study 8120686 — intervention group
Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 156
Study 3122277 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 mcg
Number of subjects: 0
Study 3122277 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 mcg
Number of subjects: 0
Study 3122277 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mcg
Number of subjects: 0
Study 3122277 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (various doses)
Number of subjects: 0
Study 3122277 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 31401795 — intervention group
Group type: EXPERIMENTAL
Intervention: SNF472 (intravenous formulation of myo-inositol hexaphosphate) administered 3 times per week for 12 weeks
Number of subjects: 14
Study 27893019 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt-needle injection (lidocaine, 2%; 27-gauge needle)
Number of subjects: 44
Study 27893019 — intervention group
Group type: COMPARATOR
Intervention: Sharp-needle injection
Number of subjects: 44
Study 27893019 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt-needle injection
Number of subjects: 44
Study 26463698 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 273
Study 26463698 — intervention group
Group type: COMPARATOR
Intervention: No GTN
Number of subjects: 273
Study 23822690 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (50 mg/kg body wt)
Number of subjects: 10
Study 23822690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20630667 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-T MRI
Number of subjects: 40
Study 20630667 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-T MRI
Number of subjects: 40
Study 20630667 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 40